Cytotoxicity and Selectivity Profiling

We maintain a panel of over 30 tumor cell lines covering lung, breast, ovarian, pancreatic, colorectal carcinomas, leukemias, and lymphomas. Primary cells such as PBMCs and iPSC-derived cells, as well as custom genetically engineered lines, are available on request.

Yes. For antibody-drug conjugates, monoclonal antibodies, and bispecific engagers, we offer cell-dependent cytotoxicity assays using PBMCs, cytotoxic T cells, or NK cells as effector populations. We also support custom target cell lines expressing your antigen.

Selectivity index is defined as the ratio of the toxic concentration (IC50 in a relevant normal cell line or against an off-target enzyme) to the effective bioactive concentration (IC50 in the target cell line or against the primary target). An SI >10 is often considered desirable for further development.

Each report includes raw data and plate maps, dose-response curves with IC50 values and performance scoped per project confidence intervals, selectivity heatmaps, QC metrics (Z' factor, replicate concordance), and a written summary with go/no-go recommendations.

Yes. We can design custom assay protocols to test compounds in combination with immune effector molecules, other drugs, or in co-culture systems. Project scoping will define the appropriate conditions.

The expected timeline will be defined during project scoping and included in your study proposal.